# Identifying correlates of protection afforded by (Delta)GY SIVmac239 attenuated virus vaccine

> **NIH NIH N01** · TULANE UNIVERSITY OF LOUISIANA · 2020 · $602,145

## Abstract

The development of HIV vaccines and other prevention strategies relies on the use of nonhuman primates in preclinical studies to advance the development of effective AIDS vaccine candidates and to advance development of effective topical microbicides and other prevention modalities or immune-based therapies. The NIAID Simian Vaccine Evaluation Unit (SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators. These studies complement NIAID-supported basic vaccine research and vaccine evaluation studies funded through R01 (investigator-initiated research) grants, HIVRAD (HIV Vaccine Research and Design Program) grants, IPCAVD (Integrated Preclinical-Clinical AIDS Vaccine Development) grants, and NHP Consortium awards. The SVEUs also perform studies of candidate vaccines offered by companies or other researchers.

## Key facts

- **NIH application ID:** 10074408
- **Project number:** 272201300004I-P00005-27200006-1
- **Recipient organization:** TULANE UNIVERSITY OF LOUISIANA
- **Principal Investigator:** PYONE AYE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $602,145
- **Award type:** —
- **Project period:** 2016-12-07 → 2020-10-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10074408

## Citation

> US National Institutes of Health, RePORTER application 10074408, Identifying correlates of protection afforded by (Delta)GY SIVmac239 attenuated virus vaccine (272201300004I-P00005-27200006-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10074408. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*